(P133) Variation in Insurance Status by Patient Demographics and Tumor Site Among the Top Twenty-Five Causes of Cancer

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

In the United States, an estimated 48 million individuals live without health insurance. The purpose of this study is to explore differences in key factors associated with insurance status among non-Medicare-aged adults diagnosed with the top 25 incident cancers using the Surveillance, Epidemiology, and End Results (SEER) public-use database.

Stephen R. Grant, BS, Gary V. Walker, MD, MPH, Ashleigh Guadagnolo, MD, MPH, Matthew Koshy, MD, Usama Mahmood, MD; UT MD Anderson Cancer Center

Background: In the United States, an estimated 48 million individuals live without health insurance. The purpose of this study is to explore differences in key factors associated with insurance status among non-Medicare-aged adults diagnosed with the top 25 incident cancers using the Surveillance, Epidemiology, and End Results (SEER) public-use database.

Methods: A total of 688,794 patients aged 18-64 years diagnosed with 1 of the top 25 incident cancers (representing 95% of all cancer diagnoses) between 2007 and 2010 in the SEER database were analyzed. Patient characteristics included age, race, gender, marital status, rural residence, and tumor stage. County-level demographics included percent poverty level. Insurance status was defined as insured, Medicaid, or uninsured. A multivariate logistic regression model was used to determine factors associated with lack of insurance.

Results: Of the 688,794 eligible patients, 536,297 (77.9%) had insurance, 76,516 (11.1%) had Medicaid, and 33,798 (4.9%) did not have insurance. On univariate analysis, the following demographic characteristics were associated with lack of insurance: younger age, male gender, nonwhite race, being unmarried, rural residence, and residing in a county with higher poverty level (all P < .0001). The cancer types with the highest rates of insurance coverage were prostate cancer (92.3%), melanoma of the skin (92.5%), and thyroid cancer (89.5%). The lowest rates of insurance were seen among patients with cancer of the cervix (64.2%), liver (67.9%), and stomach (70.9%). Among those uninsured, the top three causes of cancer were lung cancer (14.9%), colorectal cancer (12.1%), and breast cancer (10.2%). Among those with Medicaid, the top three causes of cancer were breast cancer (21.3%), lung cancer (15.7%), and colorectal cancer (9.2%). Males were more likely to be uninsured (5.8% vs 4.7%), and females were more likely to have Medicaid (13.3% vs 10.2%) (P < .0001). Insurance rates increased with age and ranged from 73.6% for 18–29-year-olds to 85.8% for 60–64-year-olds (P < .0001). Nonwhite individuals represented 45.5% of the uninsured vs only 26.9% of the insured (P < .0001). The rate of insurance decreased from 84.1% in 2007 to 81.5% in 2010 (P < .0001). In a multivariate logistic regression, younger age, female gender, nonwhite race, being unmarried, rural residence, and residence in a county with a higher percent below poverty were associated with the lack of insurance.

Conclusions: Large disparities exist in the rates of insurance by cancer type. Younger age, female gender, nonwhite race, being unmarried, rural residence, and residence in a county with a higher percent below poverty were associated with lack of insurance. The expansion of private insurance would be expected to disproportionally benefit certain populations and cancer types.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Related Content